Lv4
742 积分 2023-10-17 加入
The next generation of immunotherapies for lung cancers
7天前
已完结
Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy
9天前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
1个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
1个月前
已完结
Small cell lung cancer
1个月前
已完结
Controlled backfill in oncology dose-finding trials
1个月前
已完结
Antibody-drug conjugates: A review of cutaneous adverse effects
1个月前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2个月前
已完结
Interstitial lung disease biomarkers: a systematic review and meta-analysis
3个月前
已完结
Small-Cell Lung Cancer in Never-Smokers: A Case Series With Information on Family History of Cancer and Environmental Tobacco Smoke
3个月前
已完结
皖公网安备34019202002308
